Last reviewed · How we verify
Ervebo
At a glance
| Generic name | Ervebo |
|---|---|
| Also known as | r-VSV-ZEBOV vaccine, VSV-ZEBOV |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunology of Ebola Vaccine (PHASE2)
- EBOla Post-Exposure Prophylaxis (PHASE3)
- Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers (PHASE2)
- REVIVE (Response to the Ebola Virus Vaccine) (PHASE4)
- Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure (PHASE3)
- Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC (PHASE3)
- Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses (PHASE4)
- Prophylaxis Vaccine Antibodies Ebola (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |